Abstract: A series of novel cyclic urea molecules 5,6-dihydroxy-1,3-diazepane-2,4,7-trione as HIV-1 protease inhibitors were designed using computational techniques. The designed molecules were compared with the known cyclic urea molecules by performing docking studies, calculating their ADME (Absorption, Distribution, Metabolism, and Excretion) properties and protein ligand interaction energy. These novel molecules were designed by substituting the P 1 /P 1 positions (4 th and 7 th position of 1, 3-diazepan-2-one) with double bonded oxygens. This reduces the molecular weight and increases the bioavailability, indicating better ADME properties. The docking studies showed good binding affinity towards HIV-1 protease. The biological activity of these inhibitors were predicted by a model equation generated by the regression analysis between biological activity (log 1/K i ) of known inhibitors and their protein ligand interaction energy. The synthetic studies are in progress.
Introduction
AIDS is one of the most serious health problems today. Human immune virus type 1 (HIV-1) is the main agent causing AIDS. Inhibition of virally encoded protease has been demonstrated to be an effective antiviral drug therapy against HIV-1 infection. [1] [2] [3] [4] [5] Several HIV-1 protease inhibitors have been shown to reduce the viral load and increase the number of CD4 + lymphocytes in HIV infected patients. [6] [7] [8] HIV protease inhibitors belong to three different classes as reported in the literature, nonhydrolysable transition state isosteres, similar to renin inhibitors; pseudo symmetrical and C-2 symmetrical compounds [9] and nonpeptidic inhibitors [10] . Cyclic ureas have shown good HIV protease inhibition. The cyclic urea classes of inhibitors are designed to displace a unique structural water molecule present in the HIV-1 protease active site. [11] These inhibitors have the hydroxyl groups and carbonyl oxygen in the appropriate site which is an essential factor for high potency. The diols i.e, the hydroxyl groups interact with ASP25/25' and the carbonyl oxygen with ILE50/50'. Amino acid residues like ASP30/30', GLY48/48' and ARG8/8' present in the active site also play an important role in inhibitor binding.
Method and Software
The computational work was run on a 3.2 GHz Intel Pentium-4 systems. The software Sybyl 7.0 was used for protein minimization, ligand docking and protein ligand complex minimization. Qikprop 2.5 [12] was used to calculate the ADME properties of the ligands, PEARLS [13] a web based program was used to calculate protein ligand interaction energy.
HIV-1 protease crystal structure was downloaded from Protein Data Bank (ID: 1 PRO) [14] . Minimization process was carried out using a conjugate gradient method, by applying Gauister-Huckel charges using tripos force field; the minimizations was terminated when the gradient fell below 0.01 kcal/mol. About 50 ligand molecules were selected; these ligands were constructed and then optimized by the above mentioned process. The ADME properties (required pharmacokinetic properties of viable drug compounds) were calculated by Qikprop 2.5. These ligands were docked into the protein active site using FlexX [15] docking program; FlexX uses a rigid protein and a flexible ligand. The problem of protein flexibility is addressed by minimization of docked protein ligand complex [16, 17] , as it is a time consuming method. Only those protein ligand complexes were chosen, where the ligands were properly docked into the active site of protein. These were minimized and complexation energies were calculated. Their protein ligand interaction energies were calculated using PEARLS. The complexation energy of a reversible inhibitor can be calculated from the reaction between protein (HIV-1 PR) and inhibitor (I) as represented in the following equilibrium.
Protein (HIV PR) + Inhibitor (I) ⇐⇒ Complex (HIVPR-I)
(1) Fig. 1 Structures of known cyclic urea inhibitors with P 2 substitutions, other P 2 and P 1 substitutions given in Table 1 .
Result and Discussion
The ADME properties of cyclic urea chosen from literature [18] [19] [20] [21] [22] [23] [24] (structures shown in Figure 1 ) with varied range of inhibition constants were calculated. The ADME properties showed poor bioavailability. The required pharmacokinetic properties for a viable drug compound are: [25] 
The first three are based on the Lipinski rule of five [26] , molecular weight less than 650, partition coefficient between octanol and water (log P o/w) between −1 and 6.5 and solubility (log S) greater than −7. P mdck and log BB parameter tells us about the ability of the drug to pass through blood brain barrier which is mandatory for inhibition of HIV infection. This is because the central nervous system, including the brain, is an important reservoir of HIV infection and if the antiretroviral drug does not penetrate through the blood brain barrier this leads to sub-therapeutic levels of drugs in brain. The ADME values of known inhibitors are given in Table 1 .
The compound CU 1 the best molecule in the series with K i 0.011 nM had Pmdck value (5.428) and log BB value (−3.192) less than required. The best docked compound from the series CU 3 and CU 4 has docking scores of −33.7 and −34.4 respectively (Dock scores are provided in Table 3 ) has high molecular weight, their log P o/w (7.681 and 9.394 respectively) and log S (−10.367 and −12.233 respectively) value were not in the acceptable range. The study of protein ligand interaction mainly the hydrogen bonding interaction showed that the hydroxyl group and the carbonyl oxygen had the interaction with amino acids ASP 25/25' and ILE 50/50' respectively, and only the P 2 /P 2 substitution had hydrogen bonding interaction with amino acid residues like ASP 30/30', GLY 48/48' ARG 8/8'. The P 1 /P 1 substitutions were not contributing toward the hydrogen bond interaction. The new molecules (Trione) were designed with different substitutions at the P 2 /P 2 positions and substituting the P 1 /P 1 positions with double bonded oxygen to reduce the molecular weight and increase the bioavailability (structures are shown in Figure 2 ). These molecules were first screened for their drug like properties (ADME are provided in Table 2 ). The screened molecules were docked into the protein active site. These showed good docking scores compared to known inhibitors. A regression analysis of biological activity (log 1/K i ) and protein ligand interaction energies (P LIE) calculated from PEARLS for known inhibitor was carried out and the scatter plot is shown in Figure 3 Predicted on 2 nd graph and label x and y axes on second plot too. Biological activities of the new inhibitors were predicted from the equation (3). The compounds which had better ADME properties showed comparable biological activity with that of known inhibitors. Compound trione-3 and 4 with biological activity of 9.446 and 9.59 respectively were lower than known inhibitor CU 1 (10.95) but equal to CU-3 and 4 (9.52 and 9.44 respectively). Since the ADME properties of the new inhibitors are better than the existing ones these molecules can be considered for further studies as hit molecules. 
Conclusion
From the docking study and protein ligand interaction energies studies of the Trione compared to the known cyclic urea inhibitors it can be concluded that the new molecules can be considered as a potent inhibitor of HIV-1 protease. Compounds like trione-2, 3, 4, 5 and 6 which have better ADME properties can be taken as best hit molecules and can be considered for further studies like QSAR, synthetic studies and biological activity studies. 
